Atlas Trials

Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea

Clinical trial NCT02137629 · COMPLETED

Trial details

NCT number
NCT02137629
Sponsor
Celgene
Status
COMPLETED
Study type
OBSERVATIONAL
Myelodysplastic Syndrome
Start date
2010-12-27
Primary completion
2016-05-19
Enrollment
511

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.